Sign In
Buy RLYB
$16.07
-0.160 (-0.99%)
At Close: Jun 03, 2026
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders
10:49am, Monday, 02'nd Mar 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Rallybio Corporation (NASDAQ: RLYB) and Candid Therapeutics, Inc. Upon completion of the propos
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
08:00am, Monday, 02'nd Mar 2026
NEW HAVEN, Conn. & SAN DIEGO--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a lead
Short Interest in Rallybio Corporation (NASDAQ:RLYB) Declines By 72.5%
04:29am, Friday, 27'th Feb 2026
Rallybio Corporation (NASDAQ: RLYB - Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 38
Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026
10:46am, Tuesday, 17'th Feb 2026
Complement-mediated diseases arise from overactivation or dysfunction of the complement system, a part of the innate immune system.
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
08:00am, Tuesday, 17'th Feb 2026
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati
Stock Splits Matter: What’s Coming Up This Month?
10:05am, Wednesday, 04'th Feb 2026
Here is a look at why companies split their stocks and why it matters. Upcoming splits worth keeping an eye on include one by Southern Copper..
Rallybio Announces Reverse Stock Split of Common Stock
04:05pm, Tuesday, 03'rd Feb 2026
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
08:00am, Thursday, 06'th Nov 2025
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
08:00am, Thursday, 25'th Sep 2025
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
08:00am, Wednesday, 03'rd Sep 2025
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
09:44am, Tuesday, 08'th Jul 2025
Rallybio Corporation RLYB agreed on Tuesday to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
08:00am, Tuesday, 08'th Jul 2025
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
08:00am, Thursday, 08'th May 2025
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
12:00pm, Wednesday, 09'th Apr 2025
Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
01:01pm, Tuesday, 08'th Apr 2025
Rallybio Corporation RLYB on Tuesday discontinued the RLYB212 program to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT).
